Karen Merritt
Karen Merritt/LinkedIn

Karen Merritt: New FDA Labeling Reinforces DPYD Testing Before Treatment

Karen Merritt, Patient Advocate at Advocates for Universal DPD/DPYD Testing, shared a post on LinkedIn:

Hot off the presses!

FDA updated Xeloda/capecitabine labeling with a boxed warning to include testing for DPYD variants BEFORE treatment!”

Karen Merritt

More posts featuring Capecitabine.